Reviva Pharmaceuticals reports Q3 EPS (25c), consensus (25c)

3 days ago · Reviva Pharmaceuticals reports Q3 EPS (25c), consensus (25c) November 14, 2024 — 05:30 pm EST. Written by TheFly for TipRanks -> As of September 30, 2024, the …

CouponFollow Extension

$8
OFF

Reviva Pharmaceuticals Holdings Inc Reports Q3 2024 GAAP EPS …

1 week from now

Net Loss: Reported a net loss of approximately $8.4 million for Q3 2024, an improvement from the $11.3 million loss in Q3 2023. Earnings Per Share (EPS): GAAP EPS was -$0.25, showing …

gurufocus.com

$0.26
OFF

Reviva Pharmaceuticals (RVPH) Earnings Date And Reports 2024

1 week from now

Reviva Pharmaceuticals announced Q2 2024 earnings on August 14, 2024, reporting an EPS of -$0.26, which beat the consensus estimate of -$0.28 by $0.02. With a trailing EPS of -$1.11 , …

marketbeat.com

FAQs about Reviva Pharmaceuticals reports Q3 EPS (25c), consensus (25c) Coupon?

When is Reviva Pharmaceuticals's next earnings date?

Reviva Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 21st, 2023 based off prior year's report dates. When is Reviva Pharmaceuticals's earnings date? ...

When will Reviva Pharmaceuticals (rvph) earnings release?

Reviva Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 21st, 2023 based off last year's report dates. Learn more on RVPH's earnings history. ...

Should you buy Reviva Pharmaceuticals holdings (rvph)?

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Reviva Pharmaceuticals Holdings ( RVPH – Research Report) and keeping the price target at $14.00. Ram Selvaraju has given his Buy rating due to a combination of factors that bolster confidence in Reviva Pharmaceuticals Holdings’ future prospects. ...

How much does Reviva Pharmaceuticals earn per share?

Reviva Pharmaceuticals has generated ($1.15) earnings per share over the last year ( ($1.15) diluted earnings per share). Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.99) to ($0.92) per share. ...

What does Reviva Pharmaceuticals do?

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. ...

Why has Ram Selvaraju rated Reviva Pharmaceuticals Holdings a buy?

Ram Selvaraju has given his Buy rating due to a combination of factors that bolster confidence in Reviva Pharmaceuticals Holdings’ future prospects. Of particular significance is the granting of a new U.S. patent for brilaroxazine, which covers its use in treating various forms of pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). ...